Table of contents
- What are the practical implications of this case?
- Skilled team
- Collocation
- What was the background?
- What did the court decide?
- Case details
Article summary
IP analysis: Illumina has patents to DNA sequencing technology. It issued proceedings against various Beijing Genomics Institute (BGI) companies in several EU countries, and also in the US and Hong Kong. The UK patents court’s judgment includes the first application by the lower courts of the Supreme Court’s 2020 decision in Regeneron. It also provides useful guidance on various other issues, including the identity of the skilled person and collocation. Written by Giles Parsons, partner, at Browne Jacobson.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial
Access this content for free with a 7 day trial of LexisNexis and benefit from:
- Instant clarification on points of law
- Smart search
- Workflow tools
- 42 practice areas
Get your quote today and take step closer to being able to benefit from:
- Instant clarification on points of law
- Smart search
- Workflow tools
- 36 practice areas
Get a quote for Lexis+
* denotes a required field
CONTACT US
